Organogenesis Holdings, Inc. Class A (ORGO)

NASDAQ:
ORGO
| Latest update: Mar 9, 2026, 6:41 PM

Price Chart

$2.67

4.29%
(1 month)

Top Shareholders

Morgan Stanley
9.17%
Soleus GP LLC
7.87%
Assenagon SA
4.36%
The Vanguard Group, Inc.
3.91%
BlackRock, Inc.
3.75%
First Light Asset Management LLC
3.04%
Deutsche Bank AG
2.60%
Dimensional Holdings, Inc.
2.15%

Sentiment for ORGO

News
Social

Buzz Talk for ORGO

Today

Social Media

General

Stock events for Organogenesis Holdings, Inc. (ORGO)

Organogenesis Holdings, Inc. stock has experienced significant volatility over the past six months. While the company reported strong financial results for Q4 2025, the stock fell due to market concerns over regulatory changes and competitive pressures. The company warned of a potential revenue decline in 2026 due to regulatory disruptions. Analyst ratings have varied, with some upgrading the stock and others decreasing the price target. Insider selling has also been noted.

Demand Seasonality affecting Organogenesis Holdings, Inc.’s stock price

Information regarding specific demand seasonality for Organogenesis Holdings, Inc. products and services was not explicitly found in the provided search results.

Overview of Organogenesis Holdings, Inc.’s business

Organogenesis Holdings, Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets. The company offers a diverse portfolio of bioactive and acellular biomaterials products, including advanced wound care products like Apligraf and Dermagraft, and surgical and sports medicine products like NuShield and PuraForce. Organogenesis also has pipeline products such as ReNu, which is in Phase 3 trials for knee osteoarthritis, with a BLA submission expected to be completed in the first half of 2026.

ORGO’s Geographic footprint

Organogenesis Holdings, Inc. is headquartered in Canton, Massachusetts, U.S. The company generates substantially all of its sales within the United States, serving hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.

ORGO Corporate Image Assessment

Organogenesis' brand reputation has been influenced by both positive and challenging events in the past year. Impressive revenue growth and optimistic analyst ratings contribute positively, as does the initiation of the BLA submission for ReNu. However, the projected revenue decline for 2026 due to CMS regulatory changes and investigations by law firms could negatively impact its brand perception and investor confidence.

Ownership

Organogenesis Holdings, Inc. is a publicly traded entity on the Nasdaq Capital Market under the ticker ORGO. Its ownership structure includes a mix of institutional and individual investors. Major institutional holders include Morgan Stanley, Soleus Capital Management, and Vanguard Group Inc. Individual investors include members of the founding Ades family and CEO Gary S. Gillheeney, Sr.

FAQ

What is the current stock price of Organogenesis Holdings, Inc.?

As of the latest update, Organogenesis Holdings, Inc.'s stock is trading at $2.67 per share.

What’s happening with Organogenesis Holdings, Inc. stock today?

Today, Organogenesis Holdings, Inc. stock is down by -4.29%, possibly due to news.

What is the market sentiment around Organogenesis Holdings, Inc. stock?

Current sentiment around Organogenesis Holdings, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Organogenesis Holdings, Inc.'s stock price growing?

Over the past month, Organogenesis Holdings, Inc.'s stock price has decreased by -4.29%.

How can I buy Organogenesis Holdings, Inc. stock?

You can buy Organogenesis Holdings, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol ORGO

Who are the major shareholders of Organogenesis Holdings, Inc. stock?

Major shareholders of Organogenesis Holdings, Inc. include institutions such as Morgan Stanley (9.17%), Soleus GP LLC (7.87%), Assenagon SA (4.36%) ... , according to the latest filings.